Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Apellis Pharmaceuticals Inc Market Cap
Based on ratings from 16 stock analysts, the Apellis Pharmaceuticals Inc stock price is expected to increase by 14.57% in 12 months. This is calculated by using the average 12-month stock price forecast for Apellis Pharmaceuticals Inc. The lowest target is $49.00 and the highest is $110.00. Please note analyst price targets are not guaranteed and could be missed completely.
APLS is a stock in Health Care which has been forecasted to be worth $77.44 as an average. On the higher end, the forecast price is $110.00 USD by steven seedhouse from Raymond James and on the lower end APLS is forecasted to be $49.00 by graig suvannavejh from Mizuho Securities.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| eliana merle UBS | Buy | $87.0 | maintained | Feb 13, 2024 |
| steven seedhouse Raymond James | Buy | $110.0 | maintained | Feb 5, 2024 |
| colleen m. kusy Robert W. Baird | Buy | $81.0 | reiterated | Feb 5, 2024 |
| akash tewari Jefferies | Buy | $80.0 | upgraded | Feb 4, 2024 |
| justin kim Oppenheimer | Buy | $79.0 | maintained | Jan 30, 2024 |
| derek archila Wells Fargo | Hold | $62.0 | rated | Jan 26, 2024 |
| tazeen ahmad Bank of America Securities | Buy | $77.0 | maintained | Jan 26, 2024 |
| joseph stringer Needham | Buy | $75.0 | maintained | Jan 24, 2024 |
| anupam rama J.P. Morgan | Buy | $78.0 | maintained | Jan 19, 2024 |
| chris howerton Jefferies | Hold | $68.0 | maintained | Jan 18, 2024 |
| douglas tsao H.C. Wainwright | Buy | $92.0 | rated | Jan 17, 2024 |
| graig suvannavejh Mizuho Securities | Hold | $49.0 | maintained | Jan 16, 2024 |
| annabel samimy Stifel Nicolaus | Buy | $84.0 | maintained | Jan 12, 2024 |
| laura chico Wedbush | Hold | $60.0 | maintained | Jan 12, 2024 |
| salveen richter Goldman Sachs | Buy | $90.0 | maintained | Jan 9, 2024 |
| phil nadeau TD Cowen | Buy | None | maintained | Jan 8, 2024 |
| yigal nochomovitz Citi | Buy | $67.0 | rated | Dec 14, 2023 |
| umer raffat Evercore ISI | Buy | None | reiterated | Jul 17, 2023 |
| madhu kumar Goldman Sachs | Buy | $146.0 | maintained | Jun 27, 2023 |
| akinori ueda Goldman Sachs | Buy | $146.0 | maintained | Jun 11, 2023 |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
When did it IPO
2017
Staff Count
767
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Cedric Francois M.D., Ph.D.
Market Cap
$7.93B
In 2023, APLS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that APLS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
JAZZ-USD
$126.36
LNW-USD
$89.71
PCVX-USD
$75.26
ACHC-USD
$84.63
APPF-USD
$230.24
GNTX-USD
$35.26
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
